This study focuses on platinum-based chemotherapy-induced cardiotoxicity, covering its mechanisms, manifestations, detection, management, and future directions. Mechanisms include oxidative stress, direct myocardial/DNA damage, mitochondrial dysfunction, and altered signaling (e.g., MAPK, PI3K/Akt). Manifestations range from asymptomatic left ventricular dysfunction to severe conditions like heart failure and Takotsubo cardiomyopathy. Detection relies on advanced imaging (echocardiography with GLS, CMR) and biomarkers (cardiac troponins). Management involves cardioprotective agents (ACEIs, β-blockers) and regimen adjustment. Innovations include nanoliposomal/cubosomal formulations, iPSC-derived cardiomyocyte screening, zebrafish models, and in silico modeling. Clinically, it emphasizes multidisciplinary collaboration and early monitoring to balance cancer therapy efficacy and cardiac safety.
